Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
NuCana is a biotechnology business based in the US. NuCana shares (NCNA) are listed on the NASDAQ and all prices are listed in US Dollars. NuCana employs 31 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $1.55 |
|---|---|
| 52-week range | $0.52 - $3.32 |
| 50-day moving average | $1.03 |
| 200-day moving average | $1.07 |
| Wall St. target price | $3.73 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.92 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.55 from 2023-02-02
| 1 week (2023-01-27) | 9.93% |
|---|---|
| 1 month (2023-01-04) | 85.23% |
| 3 months (2022-11-04) | 46.23% |
| 6 months (2022-08-04) | -14.36% |
| 1 year (2022-02-03) | -44.84% |
|---|---|
| 2 years (2021-02-04) | -75.82% |
| 3 years (2020-02-04) | 5.32 |
| 5 years (2018-02-02) | 23.13 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -32.9% |
| Return on equity TTM | -46.82% |
| Profit margin | 0% |
| Book value | $1.02 |
| Market capitalisation | $82.5 million |
TTM: trailing 12 months
We're not expecting NuCana to pay a dividend over the next 12 months.
Over the last 12 months, NuCana's shares have ranged in value from as little as $0.517 up to $3.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NuCana's is 0.9379. This would suggest that NuCana's shares are less volatile than average (for this exchange).
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.